Would an IMI work in Japan? EFPIA thinks so
This article was originally published in Scrip
Speaking as the president of the European pharmaceutical industry federation EFPIA, Christopher Viehbacher is quite clear that change and innovation in all areas, ranging from R&D to regulatory approaches to new drugs themselves, are essential if healthcare systems are to prosper.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.